Clinical Trial News and Research

RSS

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

Duke University and the University of Colorado schools of medicine have received a $10 million grant from the National Institute for Nursing Research (NINR), part of the National Institutes of Health, to continue the development of the Palliative Care Research Cooperative Group (PCRC) over the next five years.

24 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

ACM Global Central Laboratory, a diagnostic central laboratory specializing in delivering high quality testing services which optimize clinical trial outcomes, today announced it has acquired Phoenix Pharma Central Services Pte. Ltd, a premier central laboratory services provider for Asia Pacific clinical trials, with laboratory facilities in Singapore and Shanghai, China. The acquisition enables ACM Global to deliver increased operational and financial efficiencies to clients conducting clinical studies in the Asia Pacific region. Terms of the transaction were not disclosed.

23 Jan 2014

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

23 Jan 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

Researchers examine how neurons in brain control arm movements

Sometimes that's how our brains work. When we anticipate a physical act, such as reaching for the keys we noticed on the table, the neurons that control the task adopt a state of readiness, like sprinters bent into a crouch.

23 Jan 2014

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

The Jackson Laboratory, in collaboration with Seoul National University, will receive a five-year, $7.5 million grant from the South Korean government for a large-scale cancer genomics project employing the latest sequencing technology and special JAX mouse models that can host human tumors.

22 Jan 2014

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.

22 Jan 2014

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

Clinical trials used by the Food and Drug Administration (FDA) to approve new drugs between 2005 and 2012 vary widely in their characteristics, according to a study in the January 22/29 issue of JAMA.

22 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.

21 Jan 2014

Affymetrix gets FDA clearance to market CytoScan Dx Assay

Affymetrix, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its CytoScan Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children's developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.

21 Jan 2014

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

As co-ordinator of the European project ‘ReBioStent’, Ceram, the international materials technology company, is pleased to announce that the project, to develop new biomaterials and new arterial stents, has been awarded Euro 5.874M by the European Union.

20 Jan 2014

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

Gastroesophageal Reflux Disease (GERD) is a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.

20 Jan 2014

New, "designer" dietary fiber may eliminate side effects of current IBS treatment

A newly-developed, "designer" dietary fiber with an added potential prebiotic effect may eliminate the side effects of current treatment for Irritable Bowel Syndrome which affects 10-20 percent of the population, disproportionately women.

20 Jan 2014

$Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL$

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.

18 Jan 2014

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.

17 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Clinical Trial News and Research

Scientists receive $10M grant to continue development of Palliative Care Research Cooperative Group

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

ACM Global acquires Phoenix PCS to expand operation in the Asia Pacific region

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

New drug helps children and young adults who have severe pain from sickle cell disease

Researchers examine how neurons in brain control arm movements

Jackson Laboratory collaborates with Seoul National University to develop new mouse models, tumor repository

New oral drug appears to offer hope for fighting indolent non-Hodgkin lymphoma

Study shows clinical trials used by FD to approve new drugs vary widely in characteristics

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

Affymetrix gets FDA clearance to market CytoScan Dx Assay

Ceram-lead project to develop new biomaterials and new arterial stents awarded Euro 5.874M by the European Union

Erosive GERD treatments: an interview with Professor Joaquim Moraes-Filho, University of São Paulo Medical School

New, "designer" dietary fiber may eliminate side effects of current IBS treatment

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Different subtypes of HER2+ breast cancer facilitate more effective treatment tailored to specific tumor

Biothera enhances innate immune responses to Imprime PGG drug candidate

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery